Literature DB >> 1288508

Structure/histotoxicity relationship of parenteral iron preparations.

P Geisser1, M Baer, E Schaub.   

Abstract

Commercial iron preparations with different chemical structures and stabilities which are indicated for parenteral application were analyzed. After intravenous application in mice, toxic effects were screened by histological examination of liver, kidney, adrenal, lung and spleen. The various iron complexes were classified into four groups according to their physicochemical properties (molecular mass, kinetic and thermodynamic stability). It was found that the toxic effects can be forecasted by the chemical properties. The results clearly show that not all iron preparations tested can be recommended for intravenous application. After injection, the ideal iron preparation is deposited in the reticulo-endothelial system, and not in the parenchyma of the liver, nor mainly in the periportal area. Furthermore, its renal elimination rate should be below 1% of the dose, and there should be practically no iron detectable in the tubuli. The molecular mass of an optimal product is between 30,000 and 100,000 Daltons, and the preparation does not contain any slowly degradable biopolymers, so that the incidence of allergic side effects is reduced to a minimum. Iron preparations consisting only of weak iron complexes, which liberate iron ions stochastically, should not be used for intravenous application.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1288508

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  28 in total

Review 1.  Diagnosis and management of iron deficiency anemia in patients with IBD.

Authors:  Jürgen Stein; Franz Hartmann; Axel U Dignass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-05       Impact factor: 46.802

2.  Benefits and risks of iron supplementation in anemic neonatal pigs.

Authors:  Paweł Lipinski; Rafał R Starzyński; François Canonne-Hergaux; Barbara Tudek; Ryszard Oliński; Paweł Kowalczyk; Tomasz Dziaman; Olivier Thibaudeau; Mikołaj A Gralak; Ewa Smuda; Jarosław Woliński; Agnieszka Usińska; Romuald Zabielski
Journal:  Am J Pathol       Date:  2010-09       Impact factor: 4.307

Review 3.  Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).

Authors:  Dhruvan Patel; Chinmay Trivedi; Nabeel Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

Review 4.  Ferric carboxymaltose: a review of its use in iron deficiency.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

Review 5.  Safety aspects of parenteral iron in patients with end-stage renal disease.

Authors:  G Sunder-Plassmann; W H Hörl
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 6.  Stimulating erythropoiesis in inflammatory bowel disease associated anemia.

Authors:  Georgia Tsiolakidou; Ioannis-E Koutroubakis
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 7.  Iron, anaemia, and inflammatory bowel diseases.

Authors:  C Gasche; M C E Lomer; I Cavill; G Weiss
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

8.  The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.

Authors:  Adrian Covic; Gabriel Mircescu
Journal:  Nephrol Dial Transplant       Date:  2010-02-26       Impact factor: 5.992

Review 9.  Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.

Authors:  Katherine A Lyseng-Williamson; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  [Indications and practical management of parenteral iron therapy].

Authors:  Markus Kosch; Roland M Schaefer
Journal:  Wien Klin Wochenschr       Date:  2003-06-24       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.